Cover Image

Neoadjuvant and adjuvant chemotherapy in pancreatic cancer

Only 15-20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment concepts including neoadjuvant chemotherapy are therefore needed. Following upfront resection, adjuvant chemotherapy has become mandatory to prevent e...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaiber, Ulla (Author) , Leonhardt, Carl-Stephan (Author) , Strobel, Oliver (Author) , Tjaden, Christin (Author) , Hackert, Thilo (Author) , Neoptolemos, John P. (Author)
Format: Article (Journal)
Language:English
Published: 5 November 2018
In: Langenbeck's archives of surgery
Year: 2018, Volume: 403, Issue: 8, Pages: 917-932
ISSN:1435-2451
DOI:10.1007/s00423-018-1724-8
Online Access:Resolving-System, Volltext: https://doi.org/10.1007/s00423-018-1724-8
Verlag: https://link.springer.com/article/10.1007%2Fs00423-018-1724-8
Get full text
Author Notes:Ulla Klaiber, Carl-Stephan Leonhardt, Oliver Strobel, Christine Tjaden, Thilo Hackert, John P. Neoptolemos
Description
Summary:Only 15-20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment concepts including neoadjuvant chemotherapy are therefore needed. Following upfront resection, adjuvant chemotherapy has become mandatory to prevent early tumor recurrence. The aim of this article was to summarize existing evidence on neoadjuvant and adjuvant chemotherapy in PDAC with a focus on high-level evidence based on randomized controlled phase III clinical trials.
Item Description:Gesehen am 25.10.2019
Physical Description:Online Resource
ISSN:1435-2451
DOI:10.1007/s00423-018-1724-8

Similar Items